$OSMT Insider Trading
FREE EMAIL WATCHDOG
Get free email notifications about insider trading in Osmotica Pharmaceuticals plc.
- Your email is safe with us.
- The service is free and you can unsubscribe at any time.
General | Insiders | Insider Transactions | Monthly Overview | Weekly Overview
Overview of all insider trading transactions in Osmotica Pharmaceuticals plc. Get notifications about new insider transactions in Osmotica Pharmaceuticals plc for free.
Page: 1
| Date | Ticker | Company | Owner | Relationship | Transaction | Code | Cost ($) | Shares | Transaction Value ($) | Total Shares | % Holdings |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Jun 22 2021 | OSMT | Osmotica Pharmaceu ... | WEISS FRED G | Director | Payment of Exercise | F | 2.89 | 18,584 | 53,708 | 62,784 | 81.4 K to 62.8 K (-22.84 %) |
| Jan 26 2021 | OSMT | Osmotica Pharmaceu ... | Schaub James | EVP and COO | Payment of Exercise | F | 4.46 | 9,687 | 43,204 | 318,721 | 328.4 K to 318.7 K (-2.95 %) |
| Jan 26 2021 | OSMT | Osmotica Pharmaceu ... | Klein Christopher | General Counsel & S ... | Payment of Exercise | F | 4.46 | 9,605 | 42,838 | 217,829 | 227.4 K to 217.8 K (-4.22 %) |
| Jan 26 2021 | OSMT | Osmotica Pharmaceu ... | Einhorn Andrew J. | Chief Financial Off ... | Payment of Exercise | F | 4.46 | 9,668 | 43,119 | 157,547 | 167.2 K to 157.5 K (-5.78 %) |
| Jan 26 2021 | OSMT | Osmotica Pharmaceu ... | deVries Tina Marie | EVP, Research & Dev ... | Payment of Exercise | F | 4.46 | 9,597 | 42,803 | 157,662 | 167.3 K to 157.7 K (-5.74 %) |
| Jan 26 2021 | OSMT | Osmotica Pharmaceu ... | WEISS FRED G | Director | Payment of Exercise | F | 4.46 | 5,505 | 24,552 | 81,368 | 86.9 K to 81.4 K (-6.34 %) |
| Jan 26 2021 | OSMT | Osmotica Pharmaceu ... | COWAN GREGORY L | Director | Payment of Exercise | F | 4.46 | 5,505 | 24,552 | 74,145 | 79.7 K to 74.1 K (-6.91 %) |
| Nov 23 2020 | OSMT | Osmotica Pharmaceu ... | Venkataraman Sriram | Director | Sell | J | 0.00 | 4,936,926 | 0 | 0 | 4.9 M to 0 (-100.00 %) |
| Nov 23 2020 | OSMT | Osmotica Pharmaceu ... | Burgstahler David F | Director | Sell | J | 0.00 | 4,936,926 | 0 | 0 | 4.9 M to 0 (-100.00 %) |
| Nov 23 2020 | OSMT | Osmotica Pharmaceu ... | Avista Capital Partners III GP ... | 10% Owner | Sell | J | 0.00 | 4,936,926 | 0 | 0 | 4.9 M to 0 (-100.00 %) |
| May 22 2020 | OSMT | Osmotica Pharmaceu ... | COWAN GREGORY L | Director | Payment of Exercise | F | 4.60 | 11,112 | 51,115 | 79,650 | 90.8 K to 79.7 K (-12.24 %) |
| May 22 2020 | OSMT | Osmotica Pharmaceu ... | COWAN GREGORY L | Director | Grant | A | 0.00 | 38,716 | 0 | 90,762 | 52 K to 90.8 K (+74.39 %) |
| May 22 2020 | OSMT | Osmotica Pharmaceu ... | WEISS FRED G | Director | Payment of Exercise | F | 4.60 | 17,778 | 81,779 | 86,873 | 104.7 K to 86.9 K (-16.99 %) |
| May 22 2020 | OSMT | Osmotica Pharmaceu ... | WEISS FRED G | Director | Grant | A | 0.00 | 38,716 | 0 | 104,651 | 65.9 K to 104.7 K (+58.72 %) |
| May 22 2020 | OSMT | Osmotica Pharmaceu ... | MARKISON BRIAN A | Chief Executive Off ... | Option Exercise | A | 0.00 | 249,787 | 0 | 249,787 | |
| May 22 2020 | OSMT | Osmotica Pharmaceu ... | MARKISON BRIAN A | Chief Executive Off ... | Grant | A | 0.00 | 249,787 | 0 | 2,126,020 | 1.9 M to 2.1 M (+13.31 %) |
| May 20 2020 | OSMT | Osmotica Pharmaceu ... | Klein Christopher | General Counsel and ... | Option Exercise | A | 0.00 | 71,550 | 0 | 71,550 | |
| May 20 2020 | OSMT | Osmotica Pharmaceu ... | Klein Christopher | General Counsel and ... | Grant | A | 0.00 | 71,550 | 0 | 227,434 | 155.9 K to 227.4 K (+45.90 %) |
| May 20 2020 | OSMT | Osmotica Pharmaceu ... | Einhorn Andrew J. | Chief Financial Off ... | Option Exercise | A | 0.00 | 71,550 | 0 | 71,550 | |
| May 20 2020 | OSMT | Osmotica Pharmaceu ... | Einhorn Andrew J. | Chief Financial Off ... | Grant | A | 0.00 | 71,550 | 0 | 167,215 | 95.7 K to 167.2 K (+74.79 %) |
| May 20 2020 | OSMT | Osmotica Pharmaceu ... | deVries Tina Marie | EVP, Research & Dev ... | Option Exercise | A | 0.00 | 71,550 | 0 | 71,550 | |
| May 20 2020 | OSMT | Osmotica Pharmaceu ... | deVries Tina Marie | EVP, Research & Dev ... | Grant | A | 0.00 | 71,550 | 0 | 167,259 | 95.7 K to 167.3 K (+74.76 %) |
| May 20 2020 | OSMT | Osmotica Pharmaceu ... | Schaub James | EVP and COO | Option Exercise | A | 0.00 | 73,253 | 0 | 73,253 | |
| May 20 2020 | OSMT | Osmotica Pharmaceu ... | Schaub James | EVP and COO | Grant | A | 0.00 | 73,253 | 0 | 328,408 | 255.2 K to 328.4 K (+28.71 %) |
| Jan 30 2020 | OSMT | Osmotica Pharmaceu ... | COWAN GREGORY L | Director | Payment of Exercise | F | 7.00 | 5,505 | 38,535 | 52,046 | 57.6 K to 52 K (-9.57 %) |
| Jan 30 2020 | OSMT | Osmotica Pharmaceu ... | Schaub James | EVP and COO | Payment of Exercise | F | 7.00 | 9,197 | 64,379 | 255,155 | 264.4 K to 255.2 K (-3.48 %) |
| Jan 30 2020 | OSMT | Osmotica Pharmaceu ... | Klein Christopher | General Counsel & S ... | Payment of Exercise | F | 7.00 | 9,148 | 64,036 | 155,884 | 165 K to 155.9 K (-5.54 %) |
| Jan 30 2020 | OSMT | Osmotica Pharmaceu ... | Einhorn Andrew J. | Chief Financial Off ... | Payment of Exercise | F | 7.00 | 9,184 | 64,288 | 95,665 | 104.8 K to 95.7 K (-8.76 %) |
| Jan 30 2020 | OSMT | Osmotica Pharmaceu ... | WEISS FRED G | Director | Payment of Exercise | F | 7.00 | 5,505 | 38,535 | 65,935 | 71.4 K to 65.9 K (-7.71 %) |
| Jan 30 2020 | OSMT | Osmotica Pharmaceu ... | deVries Tina Marie | EVP, Research & Dev ... | Payment of Exercise | F | 7.00 | 9,140 | 63,980 | 95,709 | 104.8 K to 95.7 K (-8.72 %) |
| Jan 15 2020 | OSMT | Osmotica Pharmaceu ... | Harsaul Foundation | 10% Owner | Buy | P | 5.00 | 1,250,000 | 6,250,000 | 22,485,297 | 21.2 M to 22.5 M (+5.89 %) |
| Jan 15 2020 | OSMT | Osmotica Pharmaceu ... | Harsaul Foundation | 10% Owner | Buy | P | 5.00 | 1,250,000 | 6,250,000 | 22,485,297 | 21.2 M to 22.5 M (+5.89 %) |
| Jan 15 2020 | OSMT | Osmotica Pharmaceu ... | Altchem Ltd | 10% Owner | Buy | P | 5.00 | 1,250,000 | 6,250,000 | 22,485,297 | 21.2 M to 22.5 M (+5.89 %) |
| Jan 15 2020 | OSMT | Osmotica Pharmaceu ... | Altchem Ltd | 10% Owner | Buy | P | 5.00 | 1,250,000 | 6,250,000 | 22,485,297 | 21.2 M to 22.5 M (+5.89 %) |
| Jan 15 2020 | OSMT | Osmotica Pharmaceu ... | Venkataraman Sriram | Director | Buy | P | 5.00 | 1,250,000 | 6,250,000 | 15,730,864 | 14.5 M to 15.7 M (+8.63 %) |
| Jan 15 2020 | OSMT | Osmotica Pharmaceu ... | Burgstahler David F | Director | Buy | P | 5.00 | 1,250,000 | 6,250,000 | 15,730,864 | 14.5 M to 15.7 M (+8.63 %) |
| Jan 15 2020 | OSMT | Osmotica Pharmaceu ... | Avista Capital Partners III GP ... | 10% Owner | Buy | P | 5.00 | 1,250,000 | 6,250,000 | 15,730,864 | 14.5 M to 15.7 M (+8.63 %) |
| Jun 19 2019 | OSMT | Osmotica Pharmaceu ... | COWAN GREGORY L | Director | Grant | A | 0.00 | 23,148 | 0 | 57,551 | 34.4 K to 57.6 K (+67.28 %) |
| Jun 19 2019 | OSMT | Osmotica Pharmaceu ... | WEISS FRED G | Director | Grant | A | 0.00 | 37,037 | 0 | 71,440 | 34.4 K to 71.4 K (+107.66 %) |
| Feb 27 2019 | OSMT | Osmotica Pharmaceu ... | MARKISON BRIAN A | Chief Executive Off ... | Grant | A | 0.00 | 387,991 | 0 | 1,876,233 | 1.5 M to 1.9 M (+26.07 %) |
| Jan 28 2019 | OSMT | Osmotica Pharmaceu ... | WEISS FRED G | Director | Grant | A | 0.00 | 34,403 | 0 | 34,403 | 0 to 34.4 K |
| Jan 28 2019 | OSMT | Osmotica Pharmaceu ... | deVries Tina Marie | EVP, Research & Dev ... | Grant | A | 0.00 | 104,849 | 0 | 104,849 | 0 to 104.8 K |
| Jan 28 2019 | OSMT | Osmotica Pharmaceu ... | Schaub James | EVP and COO | Grant | A | 0.00 | 104,849 | 0 | 264,352 | 159.5 K to 264.4 K (+65.73 %) |
| Jan 28 2019 | OSMT | Osmotica Pharmaceu ... | Einhorn Andrew J. | Chief Financial Off ... | Grant | A | 0.00 | 104,849 | 0 | 104,849 | 0 to 104.8 K |
| Jan 28 2019 | OSMT | Osmotica Pharmaceu ... | Klein Christopher | General Counsel and ... | Grant | A | 0.00 | 104,849 | 0 | 165,032 | 60.2 K to 165 K (+174.22 %) |
| Jan 28 2019 | OSMT | Osmotica Pharmaceu ... | COWAN GREGORY L | Director | Grant | A | 0.00 | 34,403 | 0 | 34,403 | 0 to 34.4 K |
Page: 1